Texas Oncology, Houston, TX, USA.
Curr Oncol Rep. 2012 Aug;14(4):295-306. doi: 10.1007/s11912-012-0237-9.
Vascular endothelial growth factor (VEGF) inhibitors have significantly improved outcomes in patients with advanced renal cell carcinoma (RCC). Multiple VEGF inhibiting orally administered tyrosine kinase inhibitors (TKIs) have been approved including sunitinib, sorafenib, pazopanib and most recently, axitinib. One VEGF inhibiting monoclonal antibody, bevacizumab, is approved in combination with interferon. However, these agents, besides the known progression-free survival benefits, are associated with a small but real risk of potentially life threatening and contrasting toxicities of thrombosis (both venous and arterial) and bleeding. Appropriate patient selection for VEGF inhibitors and prevention as well as prompt intervention to manage thrombosis and bleeding are necessary to forestall serious morbidities and mortality.
血管内皮生长因子（VEGF）抑制剂显著改善了晚期肾细胞癌（RCC）患者的预后。多种 VEGF 抑制的口服酪氨酸激酶抑制剂（TKI）已被批准，包括舒尼替尼、索拉非尼、帕唑帕尼，最近还有阿昔替尼。一种 VEGF 抑制的单克隆抗体贝伐珠单抗与干扰素联合使用。然而，这些药物除了已知的无进展生存期获益外，还与潜在的危及生命和具有显著差异的血栓形成（包括静脉和动脉）和出血毒性相关。对 VEGF 抑制剂进行适当的患者选择以及预防和及时干预以管理血栓形成和出血是预防严重发病率和死亡率所必需的。
